Drug Profile

Tigulixostat - LG Chem

Alternative Names: IBI-350; LC-350189; LR-19074

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LG Life Sciences
Developer LG Chem
Class Antigouts; Carboxylic acids; Indoles; Nitriles; Pyrazoles; Small molecules
Mechanism of Action Xanthine oxidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Gout

Most Recent Events

28 Aug 2024 No recent reports of development identified for phase-I development in Gout(In volunteers) in USA (PO, Capsule)
28 Aug 2024 No recent reports of development identified for phase-I development in Gout(In volunteers) in USA (PO, Tablet)
12 Jun 2024 Pharmacodynamics data from preclinical studies in Gout presented at the 25^th Annual Congress of the European League Against Rheumatism (EULAR-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com